146 related articles for article (PubMed ID: 21618021)
1. Four-component pharmacophore model for endomorphins toward μ opioid receptor subtypes.
Wu YC; Jaglinski T; Hsieh JY; Chiu JJ; Chiang TY; Hwang CC
J Mol Model; 2012 Feb; 18(2):825-34. PubMed ID: 21618021
[TBL] [Abstract][Full Text] [Related]
2. Conformational analysis of the endogenous mu-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modeling.
Podlogar BL; Paterlini MG; Ferguson DM; Leo GC; Demeter DA; Brown FK; Reitz AB
FEBS Lett; 1998 Nov; 439(1-2):13-20. PubMed ID: 9849868
[TBL] [Abstract][Full Text] [Related]
3. The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe3 residue to different domains of the opioid receptors.
Brandt W; Stoldt M; Schinke H
J Comput Aided Mol Des; 1996 Jun; 10(3):201-12. PubMed ID: 8808737
[TBL] [Abstract][Full Text] [Related]
4. Comparative conformational analyses of mu-selective dermorphin and delta-selective deltorphin-II in aqueous solution by 1H-NMR spectroscopy.
Segawa M; Ohno Y; Doi M; Inoue M; Ishida T; Iwashita T
Int J Pept Protein Res; 1994 Sep; 44(3):295-304. PubMed ID: 7822107
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of alphaS1-casomorphin using AM1 calculations and molecular dynamics simulations.
Wu YC; Lin JS; Hwang CC
J Phys Chem B; 2007 Jun; 111(25):7377-83. PubMed ID: 17530883
[TBL] [Abstract][Full Text] [Related]
6. Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1.
Paterlini MG; Avitabile F; Ostrowski BG; Ferguson DM; Portoghese PS
Biophys J; 2000 Feb; 78(2):590-9. PubMed ID: 10653774
[TBL] [Abstract][Full Text] [Related]
7. Low Energy Conformations for Endogenous Mu-Receptor-Specific Peptides.
Lin B; Carty RP; Pincus MR
Protein J; 2020 Jun; 39(3):217-223. PubMed ID: 32449111
[TBL] [Abstract][Full Text] [Related]
8. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation.
Keller M; Boissard C; Patiny L; Chung NN; Lemieux C; Mutter M; Schiller PW
J Med Chem; 2001 Nov; 44(23):3896-903. PubMed ID: 11689075
[TBL] [Abstract][Full Text] [Related]
9. Endomorphins and related opioid peptides.
Okada Y; Tsuda Y; Bryant SD; Lazarus LH
Vitam Horm; 2002; 65():257-79. PubMed ID: 12481550
[TBL] [Abstract][Full Text] [Related]
10. Endomorphin 1[psi] and endomorphin 2[psi], endomorphins analogues containing a reduced (CH2NH) amide bond between Tyr1 and Pro2, display partial agonist potency but significant antinociception.
Zhao QY; Chen Q; Yang DJ; Feng Y; Long Y; Wang P; Wang R
Life Sci; 2005 Jul; 77(10):1155-65. PubMed ID: 15878600
[TBL] [Abstract][Full Text] [Related]
11. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2.
Monory K; Bourin MC; Spetea M; Tömböly C; Tóth G; Matthes HW; Kieffer BL; Hanoune J; Borsodi A
Eur J Neurosci; 2000 Feb; 12(2):577-84. PubMed ID: 10712637
[TBL] [Abstract][Full Text] [Related]
12. Preferred conformation of endomorphin-1 in aqueous and membrane-mimetic environments.
Fiori S; Renner C; Cramer J; Pegoraro S; Moroder L
J Mol Biol; 1999 Aug; 291(1):163-75. PubMed ID: 10438613
[TBL] [Abstract][Full Text] [Related]
13. A novel non-opioid binding site for endomorphin-1.
Lengyel I; Toth F; Biyashev D; Szatmari I; Monory K; Tomboly C; Toth G; Benyhe S; Borsodi A
J Physiol Pharmacol; 2016 Aug; 67(4):605-616. PubMed ID: 27779481
[TBL] [Abstract][Full Text] [Related]
14. Conformational comparison of mu-selective endomorphin-2 with its C-terminal free acid in DMSO solution, by 1H NMR spectroscopy and molecular modeling calculation.
In Y; Minoura K; Ohishi H; Minakata H; Kamigauchi M; Sugiura M; Ishida T
J Pept Res; 2001 Nov; 58(5):399-412. PubMed ID: 11892849
[TBL] [Abstract][Full Text] [Related]
15. The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
Xie H; Woods JH; Traynor JR; Ko MC
Anesth Analg; 2008 Jun; 106(6):1873-81. PubMed ID: 18499626
[TBL] [Abstract][Full Text] [Related]
16. Theoretical conformational analysis of the opioid delta antagonist H-Tyr-Tic-Phe-OH and the mu agonist H-Tyr-D-Tic-Phe-NH2.
Wilkes BC; Schiller PW
Biopolymers; 1994 Sep; 34(9):1213-9. PubMed ID: 7948733
[TBL] [Abstract][Full Text] [Related]
17. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
18. Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure.
Fichna J; do-Rego JC; Janecki T; Staniszewska R; Poels J; Broeck JV; Costentin J; Schiller PW; Janecka A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1350-3. PubMed ID: 18207400
[TBL] [Abstract][Full Text] [Related]
19. Differential receptor binding characteristics of consecutive phenylalanines in micro-opioid specific peptide ligand endomorphin-2.
Honda T; Shirasu N; Isozaki K; Kawano M; Shigehiro D; Chuman Y; Fujita T; Nose T; Shimohigashi Y
Bioorg Med Chem; 2007 Jun; 15(11):3883-8. PubMed ID: 17395470
[TBL] [Abstract][Full Text] [Related]
20. Endomorphin-1 discriminates the mu-opioid receptor from the delta- and kappa-opioid receptors by recognizing the difference in multiple regions.
Ide S; Sakano K; Seki T; Awamura S; Minami M; Satoh M
Jpn J Pharmacol; 2000 Aug; 83(4):306-11. PubMed ID: 11001176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
